The Bamlanivimab+Etesevimab are anti-SARC-COVID-2 monoclonal antibodies which have received Emergency Use Authorization (EUA) from US FDA as well as conditional use approval from the MoHP, Department of Drug Administration (DDA) in Nepal.
Do you have a website? Looking for the best hosting provider? Here’s a discount code.
Latest Public Health Jobs
Latest Posts
- IPHU Short Course on “Coloniality and the Struggle for Health”
- The Hubert H. Humphrey Fellowship Program 2026-27
- Polio Advanced Course in Vaccinology (PVAC ) 2025
- Wentworth Institute of Science and Health STEM Conference Grant
- What You Need to Know from the 78th World Health Assembly (#WHA78)
Thanks for visiting us.
Disclaimer: The resources, documents, guidelines, and information on this blog have been collected from various sources and are intended for informational purposes only. Information published on or through this website and affiliated social media channels does not represent the intention, plan, or strategies of an organization that the initiator is associated with in a professional or personal capacity, unless explicitly indicated.
If you have any complaints, information, or suggestions about the content published on Public Health Update, please feel free to contact us at blog.publichealthupdate@gmail.com.
#StayUpdated
